glp-1 agonist weight gain effects Agonists - What is it? Glucagon-like peptide-1 receptor agonists and

Case study I am 58, obese (BMI 35), with pre-diabetes (borderline Type 2), hypothyroidism (on 50 microg thyroxine), high cholesterol, and multiple sclerosis

NICE recommends acamprosate, naltrexone, and disulfiram for maintaining abstinence, and nalmefene for reducing consumption in specific patient groups

If youve been thinking about taking a GLP-1 or dual GIP/GLP-1 agonist, you likely have lots of questions

For Indian pharma, the question is whether they are positioned to ride that wave or get swamped by it

The consistent tolerability profile across studies, with gastrointestinal symptoms being the most frequently reported adverse effects, reinforces the clinical feasibility of repurposing GLP-1RAs in this context